A report from the American Heart Association Scientific Sessions 2012 (November 3-7 - Los Angeles, California, USA).

Abstract

Highly impacting oral and poster presentations wherein new treatment modalities for coronary artery disease, heart failure and other common cardiovascular diseases were presented throughout the AHA Scientific Sessions 2012, including new developments in the area of lipid-modifying therapies that starred one of the high-impact late-breaking clinical trial sessions during the conference. A summary of the most relevant findings among the over 4,000 abstracts presented during the meeting are reported in the following report.

• Authors: X Rabasseda
• Journal: Drugs of today (Barcelona, Spain : 1998) (Drugs Today (Barc)) Vol. 49 Issue 1 Pg. 69-84 (Jan 2013) ISSN: 1699-3993 [Print] Spain
• PMID: 23362495 (Publication Type: Congress)
• Copyright: Copyright 2013 Prous Science, S.A.U. or its licensors. All rights reserved.

Chemical References

• Cardiovascular Agents
• Hypolipidemic Agents

Topics

• American Heart Association
• Cardiac Surgical Procedures
• Cardiovascular Agents (therapeutic use)
• Cardiovascular Diseases (diagnosis, etiology, therapy)
• Humans
• Hypolipidemic Agents (therapeutic use)
• Risk Factors
• Treatment Outcome
• United States